Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

Rituximab, Cladribine, and Temsirolimus in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma

8 stycznia 2018 zaktualizowane przez: Alliance for Clinical Trials in Oncology

Phase I/II Trial of Rituximab, Cladribine, and Temsirolimus (RCT) Therapy in Newly Diagnosed Mantle Cell Lymphoma (MCL)

This phase I/II trial studies the side effects and best dose of temsirolimus when given together with cladribine and rituximab and to see how well it works in treating patients with newly diagnosed mantle cell lymphoma. Monoclonal antibodies, such as rituximab, may interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy, such as cladribine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Temsirolimus may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving temsirolimus together with cladribine and rituximab may kill more cancer cells.

Przegląd badań

Status

Zakończony

Warunki

Interwencja / Leczenie

Szczegółowy opis

PRIMARY OBJECTIVES:

I. To assess the efficacy and safety of the combination of rituximab, cladribine, and temsirolimus for newly diagnosed mantle cell lymphoma.

II. To determine the maximum tolerated dose (MTD) of temsirolimus combined with a fixed dose and schedule of rituximab and cladribine. (Phase I) III. To assess the efficacy of the combination of rituximab, cladribine, and temsirolimus for newly diagnosed mantle cell lymphoma with the proportion of complete responses as the primary endpoint. (Phase II)

SECONDARY OBJECTIVES:

I. To assess other measures of efficacy of the regimen including progression free survival, duration of response, and overall survival.

II. To assess the toxicity profile of the combination of rituximab, cladribine, and temsirolimus.

III. To assess efficacy using traditional lymphoma parameters and absolute lymphocyte count.

IV. To assess metabolic markers (hyperglycemia, hyperlipidemia) as markers of mammalian target of rapamycin (mTOR) inhibition using the glucose and lipid measurements being performed in the clinical laboratory as part of routine care.

V. To correlate response with serum free light chains, single nucleotide polymorphisms (SNPs) in host immune genes, vitamin D metabolites, and phosphatidylinositide 3-kinase (PI3K) pathway member expression.

VI. As part of ongoing research for North Central Cancer Treatment Group (NCCTG) lymphoma studies, paraffin-embedded tissue blocks/slides and blood products will be banked for future studies.

OUTLINE: This is a phase I, dose-escalation study of temsirolimus followed by a phase II study.

Patients receive rituximab intravenously (IV) on day 1 and cladribine IV over 2 hours on days 1-5. Patients then receive temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Patients also receive filgrastim subcutaneously (SC) on days 6-15 or pegfilgrastim SC on day 6. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up every 3 months for 2 years and then every 4 months for 3 years.

Typ studiów

Interwencyjne

Zapisy (Oczekiwany)

74

Faza

  • Faza 1

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Lokalizacje studiów

  • Stany Zjednoczone
    • Arizona
      • Scottsdale, Arizona, Stany Zjednoczone, 85259-5499
        • Mayo Clinic Scottsdale
    • Illinois
      • Bloomington, Illinois, Stany Zjednoczone, 61701
        • Illinois CancerCare - Bloomington
      • Bloomington, Illinois, Stany Zjednoczone, 61701
        • St. Joseph Medical Center
      • Canton, Illinois, Stany Zjednoczone, 61520
        • Illinois CancerCare - Canton
      • Canton, Illinois, Stany Zjednoczone, 61520
        • Graham Hospital
      • Carthage, Illinois, Stany Zjednoczone, 62321
        • Memorial Hospital
      • Carthage, Illinois, Stany Zjednoczone, 62321
        • Illinois CancerCare - Carthage
      • Eureka, Illinois, Stany Zjednoczone, 61530
        • Illinois CancerCare - Eureka
      • Eureka, Illinois, Stany Zjednoczone, 61530
        • Eureka Community Hospital
      • Galesburg, Illinois, Stany Zjednoczone, 61401
        • Illinois CancerCare - Galesburg
      • Galesburg, Illinois, Stany Zjednoczone, 61401
        • Galesburg Clinic, PC
      • Havana, Illinois, Stany Zjednoczone, 62644
        • Mason District Hospital
      • Havana, Illinois, Stany Zjednoczone, 62644
        • Illinois CancerCare - Havana
      • Kewanee, Illinois, Stany Zjednoczone, 61443
        • Illinois CancerCare - Kewanee Clinic
      • Macomb, Illinois, Stany Zjednoczone, 61455
        • Illinois CancerCare - Macomb
      • Macomb, Illinois, Stany Zjednoczone, 61455
        • Mcdonough District Hospital
      • Monmouth, Illinois, Stany Zjednoczone, 61462
        • Illinois CancerCare - Monmouth
      • Monmouth, Illinois, Stany Zjednoczone, 61462
        • OSF Holy Family Medical Center
      • Normal, Illinois, Stany Zjednoczone, 61761
        • Bromenn Regional Medical Center
      • Normal, Illinois, Stany Zjednoczone, 61761
        • Community Cancer Center
      • Normal, Illinois, Stany Zjednoczone, 61761
        • Illinois CancerCare - Community Cancer Center
      • Ottawa, Illinois, Stany Zjednoczone, 61350
        • Community Hospital of Ottawa
      • Ottawa, Illinois, Stany Zjednoczone, 61350
        • Oncology Hematology Associates of Central Illinois, PC - Ottawa
      • Pekin, Illinois, Stany Zjednoczone, 61554
        • Cancer Treatment Center at Pekin Hospital
      • Pekin, Illinois, Stany Zjednoczone, 61603
        • Illinois CancerCare - Pekin
      • Peoria, Illinois, Stany Zjednoczone, 61636
        • Methodist Medical Center of Illinois
      • Peoria, Illinois, Stany Zjednoczone, 61614
        • Proctor Hospital
      • Peoria, Illinois, Stany Zjednoczone, 61637
        • OSF St. Francis Medical Center
      • Peoria, Illinois, Stany Zjednoczone, 61615
        • CCOP - Illinois Oncology Research Association
      • Peoria, Illinois, Stany Zjednoczone, 61615
        • Oncology Hematology Associates of Central Illinois, PC - Peoria
      • Peru, Illinois, Stany Zjednoczone, 61354
        • Illinois CancerCare - Peru
      • Peru, Illinois, Stany Zjednoczone, 61354
        • Illinois Valley Community Hospital
      • Princeton, Illinois, Stany Zjednoczone, 61356
        • Perry Memorial Hospital
      • Princeton, Illinois, Stany Zjednoczone, 61356
        • Illinois CancerCare - Princeton
      • Spring Valley, Illinois, Stany Zjednoczone, 61362
        • Illinois CancerCare - Spring Valley
    • Indiana
      • Elkhart, Indiana, Stany Zjednoczone, 46515
        • Elkhart General Hospital
      • Elkhart, Indiana, Stany Zjednoczone, 46514-2098
        • Elkhart Clinic, LLC
      • Elkhart, Indiana, Stany Zjednoczone, 46514
        • Michiana Hematology-Oncology, PC - Elkhart
      • Kokomo, Indiana, Stany Zjednoczone, 46904
        • Howard Community Hospital
      • La Porte, Indiana, Stany Zjednoczone, 46350
        • Center for Cancer Therapy at LaPorte Hospital and Health Services
      • Mishawaka, Indiana, Stany Zjednoczone, 46545-1470
        • Michiana Hematology-Oncology, PC - South Bend
      • Mishawaka, Indiana, Stany Zjednoczone, 46545-1470
        • Saint Joseph Regional Medical Center
      • Plymouth, Indiana, Stany Zjednoczone, 46563
        • Michiana Hematology Oncology PC - Plymouth
      • South Bend, Indiana, Stany Zjednoczone, 46601
        • Memorial Hospital of South Bend
      • South Bend, Indiana, Stany Zjednoczone, 46601
        • CCOP - Northern Indiana CR Consortium
      • Westville, Indiana, Stany Zjednoczone, 46391
        • Michiana Hematology Oncology PC - La Porte
    • Iowa
      • Ames, Iowa, Stany Zjednoczone, 50010
        • McFarland Clinic, PC
      • Cedar Rapids, Iowa, Stany Zjednoczone, 52403
        • Cedar Rapids Oncology Associates
      • Cedar Rapids, Iowa, Stany Zjednoczone, 52403
        • Mercy Regional Cancer Center at Mercy Medical Center
      • Clive, Iowa, Stany Zjednoczone, 50325
        • Medical Oncology and Hematology Associates - West Des Moines
      • Des Moines, Iowa, Stany Zjednoczone, 50309
        • CCOP - Iowa Oncology Research Association
      • Des Moines, Iowa, Stany Zjednoczone, 50309
        • John Stoddard Cancer Center at Iowa Methodist Medical Center
      • Des Moines, Iowa, Stany Zjednoczone, 50309
        • Medical Oncology and Hematology Associates at John Stoddard Cancer Center
      • Des Moines, Iowa, Stany Zjednoczone, 50314
        • Medical Oncology and Hematology Associates at Mercy Cancer Center
      • Des Moines, Iowa, Stany Zjednoczone, 50314
        • Mercy Cancer Center at Mercy Medical Center - Des Moines
      • Des Moines, Iowa, Stany Zjednoczone, 50316
        • John Stoddard Cancer Center at Iowa Lutheran Hospital
      • Mason City, Iowa, Stany Zjednoczone, 50401
        • Mercy Cancer Center at Mercy Medical Center - North Iowa
      • Sioux City, Iowa, Stany Zjednoczone, 51101
        • Siouxland Hematology-Oncology Associates, LLP
      • Sioux City, Iowa, Stany Zjednoczone, 51102
        • Mercy Medical Center - Sioux City
      • Sioux City, Iowa, Stany Zjednoczone, 51104
        • St. Luke's Regional Medical Center
    • Kansas
      • Chanute, Kansas, Stany Zjednoczone, 66720
        • Cancer Center of Kansas, PA - Chanute
      • Dodge City, Kansas, Stany Zjednoczone, 67801
        • Cancer Center of Kansas, PA - Dodge City
      • El Dorado, Kansas, Stany Zjednoczone, 67042
        • Cancer Center of Kansas, PA - El Dorado
      • Fort Scott, Kansas, Stany Zjednoczone, 66701
        • Cancer Center of Kansas - Fort Scott
      • Independence, Kansas, Stany Zjednoczone, 67301
        • Cancer Center of Kansas-Independence
      • Kingman, Kansas, Stany Zjednoczone, 67068
        • Cancer Center of Kansas, PA - Kingman
      • Lawrence, Kansas, Stany Zjednoczone, 66044
        • Lawrence Memorial Hospital
      • Liberal, Kansas, Stany Zjednoczone, 67901
        • Cancer Center of Kansas, PA - Liberal
      • Newton, Kansas, Stany Zjednoczone, 67114
        • Cancer Center of Kansas, PA - Newton
      • Parsons, Kansas, Stany Zjednoczone, 67357
        • Cancer Center of Kansas, PA - Parsons
      • Pratt, Kansas, Stany Zjednoczone, 67124
        • Cancer Center of Kansas, PA - Pratt
      • Salina, Kansas, Stany Zjednoczone, 67401
        • Cancer Center of Kansas, PA - Salina
      • Wellington, Kansas, Stany Zjednoczone, 67152
        • Cancer Center of Kansas, PA - Wellington
      • Wichita, Kansas, Stany Zjednoczone, 67208
        • Cancer Center of Kansas, PA - Medical Arts Tower
      • Wichita, Kansas, Stany Zjednoczone, 67214
        • Cancer Center of Kansas, PA - Wichita
      • Wichita, Kansas, Stany Zjednoczone, 67214
        • CCOP - Wichita
      • Wichita, Kansas, Stany Zjednoczone, 67214
        • Via Christi Cancer Center at Via Christi Regional Medical Center
      • Wichita, Kansas, Stany Zjednoczone, 67208
        • Associates in Womens Health, PA - North Review
      • Winfield, Kansas, Stany Zjednoczone, 67156
        • Cancer Center of Kansas, PA - Winfield
    • Michigan
      • Battle Creek, Michigan, Stany Zjednoczone, 49017
        • Battle Creek Health System Cancer Care Center
      • Big Rapids, Michigan, Stany Zjednoczone, 49307
        • Mecosta County Medical Center
      • Escanaba, Michigan, Stany Zjednoczone, 49431
        • Green Bay Oncology, Limited - Escanaba
      • Grand Rapids, Michigan, Stany Zjednoczone, 49503
        • Butterworth Hospital at Spectrum Health
      • Grand Rapids, Michigan, Stany Zjednoczone, 49503
        • CCOP - Grand Rapids
      • Grand Rapids, Michigan, Stany Zjednoczone, 49503
        • Lacks Cancer Center at Saint Mary's Health Care
      • Iron Mountain, Michigan, Stany Zjednoczone, 49801
        • Dickinson County Healthcare System
      • Muskegon, Michigan, Stany Zjednoczone, 49443
        • Mercy General Health Partners
      • Niles, Michigan, Stany Zjednoczone, 49120
        • Michiana Hematology Oncology PC - Niles
      • Saint Joseph, Michigan, Stany Zjednoczone, 49085
        • Lakeside Cancer Specialists, PLLC
      • Saint Joseph, Michigan, Stany Zjednoczone, 49085
        • Lakeland Regional Cancer Care Center - St. Joseph
      • Traverse City, Michigan, Stany Zjednoczone, 49684
        • Munson Medical Center
      • Wyoming, Michigan, Stany Zjednoczone, 49519
        • Metro Health Hospital
    • Minnesota
      • Burnsville, Minnesota, Stany Zjednoczone, 55337
        • Fairview Ridges Hospital
      • Coon Rapids, Minnesota, Stany Zjednoczone, 55433
        • Mercy and Unity Cancer Center at Mercy Hospital
      • Duluth, Minnesota, Stany Zjednoczone, 55805
        • CCOP - Duluth
      • Duluth, Minnesota, Stany Zjednoczone, 55805-1983
        • Duluth Clinic Cancer Center - Duluth
      • Duluth, Minnesota, Stany Zjednoczone, 55805
        • Miller - Dwan Medical Center
      • Edina, Minnesota, Stany Zjednoczone, 55435
        • Fairview Southdale Hospital
      • Fridley, Minnesota, Stany Zjednoczone, 55432
        • Mercy and Unity Cancer Center at Unity Hospital
      • Hutchinson, Minnesota, Stany Zjednoczone, 55350
        • Hutchinson Area Health Care
      • Maplewood, Minnesota, Stany Zjednoczone, 55109
        • Minnesota Oncology Hematology, PA - Maplewood
      • Maplewood, Minnesota, Stany Zjednoczone, 55109
        • HealthEast Cancer Care at St. John's Hospital
      • Minneapolis, Minnesota, Stany Zjednoczone, 55407
        • Virginia Piper Cancer Institute at Abbott - Northwestern Hospital
      • Minneapolis, Minnesota, Stany Zjednoczone, 55415
        • Hennepin County Medical Center - Minneapolis
      • Robbinsdale, Minnesota, Stany Zjednoczone, 55422-2900
        • Humphrey Cancer Center at North Memorial Outpatient Center
      • Rochester, Minnesota, Stany Zjednoczone, 55905
        • Mayo Clinic Cancer Center
      • Saint Louis Park, Minnesota, Stany Zjednoczone, 55416
        • CCOP - Metro-Minnesota
      • Saint Louis Park, Minnesota, Stany Zjednoczone, 55416
        • Park Nicollet Cancer Center
      • Saint Paul, Minnesota, Stany Zjednoczone, 55102
        • United Hospital
      • Saint Paul, Minnesota, Stany Zjednoczone, 55101
        • Regions Hospital Cancer Care Center
      • Shakopee, Minnesota, Stany Zjednoczone, 55379
        • St. Francis Cancer Center at St. Francis Medical Center
      • Stillwater, Minnesota, Stany Zjednoczone, 55082
        • Lakeview Hospital
      • Waconia, Minnesota, Stany Zjednoczone, 55387
        • Ridgeview Medical Center
      • Willmar, Minnesota, Stany Zjednoczone, 56201
        • Willmar Cancer Center at Rice Memorial Hospital
      • Woodbury, Minnesota, Stany Zjednoczone, 55125
        • Minnesota Oncology Hematology, PA - Woodbury
    • Montana
      • Billings, Montana, Stany Zjednoczone, 59101
        • CCOP - Montana Cancer Consortium
      • Billings, Montana, Stany Zjednoczone, 59101
        • St. Vincent Healthcare Cancer Care Services
      • Billings, Montana, Stany Zjednoczone, 59107-7000
        • Billings Clinic - Downtown
      • Billings, Montana, Stany Zjednoczone, 59102
        • Hematology-Oncology Centers of the Northern Rockies - Billings
      • Bozeman, Montana, Stany Zjednoczone, 59715
        • Bozeman Deaconess Cancer Center
      • Butte, Montana, Stany Zjednoczone, 59701
        • St. James Healthcare Cancer Care
      • Great Falls, Montana, Stany Zjednoczone, 59405
        • Great Falls Clinic - Main Facility
      • Great Falls, Montana, Stany Zjednoczone, 59405
        • Sletten Cancer Institute at Benefis Healthcare
      • Havre, Montana, Stany Zjednoczone, 59501
        • Northern Montana Hospital
      • Helena, Montana, Stany Zjednoczone, 59601
        • St. Peter's Hospital
      • Kalispell, Montana, Stany Zjednoczone, 59901
        • Kalispell Regional Medical Center
      • Kalispell, Montana, Stany Zjednoczone, 59901
        • Glacier Oncology, PLLC
      • Kalispell, Montana, Stany Zjednoczone, 59901
        • Kalispell Medical Oncology at KRMC
      • Missoula, Montana, Stany Zjednoczone, 59807
        • Montana Cancer Center at St. Patrick Hospital and Health Sciences Center
    • North Dakota
      • Bismarck, North Dakota, Stany Zjednoczone, 58501
        • Bismarck Cancer Center
      • Bismarck, North Dakota, Stany Zjednoczone, 58501
        • Medcenter One Hospital Cancer Care Center
      • Bismarck, North Dakota, Stany Zjednoczone, 58501
        • Mid Dakota Clinic, PC
      • Bismarck, North Dakota, Stany Zjednoczone, 58502
        • St. Alexius Medical Center Cancer Center
    • South Dakota
      • Rapid City, South Dakota, Stany Zjednoczone, 57701
        • Rapid City Regional Hospital
    • Wisconsin
      • Green Bay, Wisconsin, Stany Zjednoczone, 54307-3508
        • St. Vincent Hospital Regional Cancer Center
      • Green Bay, Wisconsin, Stany Zjednoczone, 54301-3526
        • Green Bay Oncology, Limited at St. Vincent Hospital Regional Cancer Center
      • Green Bay, Wisconsin, Stany Zjednoczone, 54303
        • Green Bay Oncology, Limited at St. Mary's Hospital
      • Green Bay, Wisconsin, Stany Zjednoczone, 54303
        • St. Mary's Hospital Medical Center - Green Bay
      • Manitowoc, Wisconsin, Stany Zjednoczone, 54221-1450
        • Holy Family Memorial Medical Center Cancer Care Center
      • Marinette, Wisconsin, Stany Zjednoczone, 54143
        • Bay Area Cancer Care Center at Bay Area Medical Center
      • Oconto Falls, Wisconsin, Stany Zjednoczone, 54154
        • Green Bay Oncology, Limited - Oconto Falls
      • Sheboygan, Wisconsin, Stany Zjednoczone, 53081
        • St. Nicholas Hospital
      • Sturgeon Bay, Wisconsin, Stany Zjednoczone, 54235
        • Green Bay Oncology, Limited - Sturgeon Bay
    • Wyoming
      • Sheridan, Wyoming, Stany Zjednoczone, 82801
        • Welch Cancer Center at Sheridan Memorial Hospital

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

18 lat i starsze (Dorosły, Starszy dorosły)

Akceptuje zdrowych ochotników

Nie

Płeć kwalifikująca się do nauki

Wszystko

Opis

Inclusion Criteria:

  • Histologically confirmed mantle cell lymphoma (MCL); the diagnosis must be confirmed by NCCTG pre-registration pathology review by Dr. Paul Kurtin or his designate; it is recommended that the biopsy be an excisional biopsy, but adequate core-needle biopsies will be accepted as long as they are considered adequate for registration by Dr. Kurtin or his designate; the tumor must be cyclin D-1 positive by immunohistochemistry or have evidence of a t(11;14) translocation by fluorescence based in situ hybridization (FISH) or cytogenetics

  • Measurable or assessable disease, defined as at least one of the following:

    • A lymph node or tumor mass that is >= 2.0 cm in at least one dimension by positron emission tomography (PET)/computed tomography (CT), CT, magnetic resonance imaging (MRI), or plain radiograph imaging
    • Splenic enlargement may be used as a measurable parameter if the spleen is palpable >= 3 cm below the left costal margin
    • Diffuse infiltration of an organ such as the stomach, bone marrow, peripheral blood, liver, lungs, or bowel by lymphoma without a discrete mass would constitute assessable, but not measurable, disease
  • Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0, 1, 2, or 3
  • Life expectancy >= 12 weeks
  • Absolute neutrophil count (ANC) >= 1,500/mm³
  • Platelet count (PLT) >= 100,000/mm³
  • Serum creatinine =< 2.0 mg/dL
  • Serum total bilirubin (or direct bilirubin if total is abnormal) =< institutional upper limit of normal (ULN) with or without secondary liver involvement
  • Serum glutamic oxaloacetic transaminase (SGOT) =< 3 x institutional ULN (exception: if there is liver involvement, SGOT must be =< 5 x institutional ULN)
  • Negative pregnancy test done =< 7 days prior to registration, for women of childbearing potential only
  • Willingness to return to NCCTG enrolling institution for follow-up
  • Willingness to provide the blood specimens as required by the protocol
  • Willingness to provide tissue specimens as required by the protocol
  • Willing to return to NCCTG enrolling institution for follow-up
  • Willing to provide blood and tissue specimens as required by the protocol
  • Willing to abstain from eating grapefruit or drinking grapefruit juice
  • Willingness to abstain from eating grapefruit or drinking grapefruit juice for the duration of the study

Exclusion Criteria

  • Any prior therapy for mantle cell non-Hodgkin lymphoma including radiation therapy; exception: patient may have undergone a splenectomy for diagnosis, cytopenia, or systematic splenomegaly
  • Active or uncontrolled infection

  • Any of the following cardiac conditions:

    • Uncontrolled high blood pressure
    • Unstable angina
    • Active congestive heart failure
    • Myocardial infarction =< 6 months
    • Serious uncontrolled cardiac arrhythmia
  • Known central nervous system (CNS) involvement

  • Any of the following:

    • Pregnant women or women of reproductive ability who are unwilling to use effective contraception while taking the drug and for 12 months after stopping treatment
    • Nursing women
    • Men who are unwilling to use a condom (even if they have undergone a prior vasectomy) while having intercourse with any woman, while taking the drug and for 12 months after stopping treatment
  • Medical or psychiatric conditions which, in the opinion of the investigator, make the patient a poor risk for participation
  • Known to be human immunodeficiency virus (HIV) positive; HIV testing is not required but should be done if clinically indicated; HIV-positive patients receiving combination anti-retroviral therapy are excluded from the study
  • Concurrent malignancy =< 5 years ago; exceptions: carcinoma in situ of the cervix, resected basal cell or squamous cell carcinomas of the skin, or prostate cancer that is in remission following a radical retropubic prostatectomy or radiation therapy; if there is a history of prior malignancy, they must not be receiving other specific treatment (other than hormonal therapy) for their cancer
  • Known hypersensitivity to rituximab or its components, or to murine proteins
  • Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm
  • Prior treatment with an mTOR inhibitor
  • Autologous or allogeneic stem cell transplant planned as part of initial therapy
  • Receiving enzyme-inducing antiepileptic drugs (enzyme inducing anti-epileptic drugs [EIAEDs]; e.g., phenytoin, fosphenytoin, carbamazepine, oxcarbazepine, phenobarbital, or primidone); any other potent cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4) inducer such as rifampin, glucocorticoids at greater than adrenal replacement levels, or St. John's wort; or receiving strong CYP3A4 inhibitors * Note: if these agents are discontinued, temsirolimus therapy can begin >= 7 days after discontinuation of such agent

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Główny cel: Leczenie
  • Przydział: Nie dotyczy
  • Model interwencyjny: Zadanie dla jednej grupy
  • Maskowanie: Brak (otwarta etykieta)

Broń i interwencje

Grupa uczestników / Arm
Interwencja / Leczenie
Eksperymentalny: Treatment (rituximab, cladribine, temsirolimus)
Patients receive rituximab IV on day 1 and cladribine IV over 2 hours on days 1-5. Patients then receive temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Patients also receive filgrastim SC on days 6-15 or pegfilgrastim SC on day 6. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
Biologiczny: Pegfilgrastym
Biologiczny: rituximab
Give IV
Lek: cladribine
Give IV
Lek: temsirolimus
Give IV
Biologiczny: Filgrastim
Give SC

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Ramy czasowe
Number of dose limiting toxicity incidents as per National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version (v) 3.0 (Phase I)
Ramy czasowe: 28 days
28 days
Proportion of complete tumor responses defined as complete remission (CR) as the objective status (Phase II)
Ramy czasowe: Up to 5 years
Up to 5 years

Miary wyników drugorzędnych

Miara wyniku
Ramy czasowe
Ogólne przetrwanie
Ramy czasowe: do 5 lat
do 5 lat
Czas przeżycia
Ramy czasowe: Do 5 lat
Do 5 lat
Progression-free survival (PFS)
Ramy czasowe: up to 5 years
up to 5 years
Time to disease progression
Ramy czasowe: up to 5 years
up to 5 years
Duration of response, defined as date at which the patient's objective status is first noted to be either a CR or partial remission to the date progression is documented
Ramy czasowe: Up to 5 years
Up to 5 years
Frequency and severity of adverse events assessed by CTCAE v3.0
Ramy czasowe: Up to 5 years
Up to 5 years

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Sponsor

Alliance for Clinical Trials in Oncology

Współpracownicy

National Cancer Institute (NCI)

Śledczy

  • Krzesło do nauki: David J. Inwards, MD, Mayo Clinic

Publikacje i pomocne linki

Osoba odpowiedzialna za wprowadzenie informacji o badaniu dobrowolnie udostępnia te publikacje. Mogą one dotyczyć wszystkiego, co jest związane z badaniem.

Publikacje ogólne

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów (Rzeczywisty)

1 kwietnia 2009

Zakończenie podstawowe (Rzeczywisty)

1 kwietnia 2012

Ukończenie studiów (Rzeczywisty)

15 czerwca 2017

Daty rejestracji na studia

Pierwszy przesłany

7 listopada 2008

Pierwszy przesłany, który spełnia kryteria kontroli jakości

7 listopada 2008

Pierwszy wysłany (Oszacować)

10 listopada 2008

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

9 stycznia 2018

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

8 stycznia 2018

Ostatnia weryfikacja

1 stycznia 2018

Więcej informacji

Terminy związane z tym badaniem

Słowa kluczowe

Dodatkowe istotne warunki MeSH

Inne numery identyfikacyjne badania

  • NCCTG-N078D
  • NCI-2009-00669 (Identyfikator rejestru: CTRP (Clinical Trials Reporting System))
  • CDR0000619329 (Identyfikator rejestru: PDQ (Physician Data Query))

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .

Subskrybuj